IGF::OT::IGF To develop HemoDefend, hemocompatible, highly porous polymer beads optimized to broadly remove freehemoglobin, potassium, reactive antibodies, and inflammatory or reactive substances from


NIH 2017 N44 HL	IGF::OT::IGF Topic 090, Phase II, Devices to Close Ductus Arteriosus in Premature Infants IGF::OT::IGF Lubock, Paul /
NIH 2017 N44 HL	IGF::OT::IGF SBIR Phase II Topic 86: Tools for Educating Children about Clinical Research Kupersmidt, Janis / Innovation Research and Training, Inc.
NIH 2016 N44 HL	Igf::Ot::Igf SBIR Topic 87: Fast Track, Base (Phase I)(Line Item 1) Cerclage for Treating Secondary Mitral Regurgitation Rafiee, Nasser / Transmural Systems, LLC
NIH 2016 N44 HL	IGF::OT::IGF SBIR Topic 094, Direct to Phase II, Transcatheter Cavopulmonary Bypass Endograft IGF::OT::IGF Rafiee, Nasser / Transmural Systems, LLC
NIH 2016 N44 HL	IGF::OT::IGF To develop HemoDefend, hemocompatible, highly porous polymer beads optimized to broadly remove freehemoglobin, potassium, reactive antibodies, and inflammatory or reactive substances from Chan, Phillip / Cytosorbents, Inc.
NIH 2015 N44 HL	Igf::Ot::Igf Shenderova, Olga / Adamas Nanotechnologies, Inc.
NIH 2015 N44 HL	Igf::Ot::Igf SBIR Topic 088, Direct-To-Phase II, Closure Devices for Transcaval Access to the Abdominal Aorta Rafiee, Nasser / Transmural Systems, LLC
NIH 2015 N44 HL	Igf::Ot::Igf SBIR Topic 076, Phase II, MRI Myocardial Biopsy Forceps Vij, Kamal / MRI Interventions, Inc.
NIH 2015 N44 HL	Igf::Ot::Igf Rampersaud, Arfaan / Columbus Nanoworks, Inc.